SYSTEMATIC REVIEW

JHND *Journal of Human Nutrition and Dietetics*   BDA The Association of UK Dietitians

The impact of branched-chain amino acid supplementation on measures of glucose homeostasis in individuals with hepatic disorders: A systematic review of clinical studies

Konstantinos Prokopidis[1] [iD] | Richard P. Kirwan[2] | Panagiotis Giannos[3] [iD] |
Konstantinos K. Triantafyllidis[4] | Konstantinos S. Kechagias[5,6] [iD] | Scott C. Forbes[7] |
Darren G. Candow[8]

[1]Department of Musculoskeletal Biology, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK

[2]School of Biological and Environmental Sciences, Liverpool John Moores University, Liverpool, UK

[3]Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, UK

[4]Department of Nutrition & Dietetics, Musgrove Park Hospital, Taunton & Somerset NHS Foundation Trust, Taunton, UK

[5]Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College, London, UK

[6]Department of Nutrition & Dietetics, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

[7]Department of Physical Education Studies, Faculty of Education, Brandon University, Brandon, MB, Canada

[8]Faculty of Kinesiology and Health Studies, University of Regina, Regina, SK, Canada

Correspondence
Konstantinos Prokopidis, Department of Musculoskeletal Biology, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L7 8XL, UK.
Email: k.prokopidis@liverpool.ac.uk

Abstract

Background: Branched chain amino acid (BCAA) supplementation may influence glucose metabolism in individuals with an impaired glyceamic profile. This systematic review investigated the effects of isolated BCAA supplementation on measures of glucose homeostasis in individuals with hepatic disorders.

Methods: We searched PubMed, Web of Science, Cochrane Library and Scopus for published clinical trials that investigated the effects of isolated BCAA supplementation on measures of glucose homeostasis, including serum glucose and insulin, glycated haemoglobin (HbA1c) levels and homeostatic model assessment for insulin resistance (HOMA-IR) scores.

Results: Eleven trials met the inclusion criteria. Only one study revealed a decrease in serum glucose from BCAA supplementation compared to three studies that showed increases. Five studies demonstrated no significant changes in serum glucose, and two studies displayed no changes in HbA1c following BCAA supplementation. Serum levels of insulin were decreased in three studies, remained unchanged in one, and increased in the remaining three studies. BCAA supplementation reduced HOMA-IR scores in two studies, increased HOMA-IR scores in another two, or resulted in no changes in two other studies.

Conclusions: BCAA supplementation in isolation had no effect on overall glucose homeostasis in individuals with hepatic disorders, although some improvements on serum insulin levels and HOMA-IR scores were observed. Overall, there is little evidence to support the utilisation of BCAA supplementation as a potential nutritional strategy for improving measures of glucose homeostasis in individuals with hepatic disorders.

KEYWORDS
BCAA, branched chain amino acids, hepatic disorders, liver disease, nutritional supplementation

Key points
- Hepatic disorders such as liver cirrhosis, hepatic encephalopathy and hepatocellular carcinoma are characterised by an impaired circulating branched-chain amino acid (BCAA) profile.

- The aim of this systematic review was to explore the effects of isolated BCAA supplementation on markers of glucose metabolism in adults with hepatic disorders.
- Qualitative analysis revealed limited benefits of isolated BCAA supplementation on overall glucose homeostasis among individuals with hepatic disorders.
- BCAA supplementation as an independent strategy is not an effective tool in improving glucose homeostasis in this population group.

INTRODUCTION

Branched-chain amino acids (BCAAs; leucine, isoleucine, valine) are essential amino acids metabolised primarily in skeletal muscle.[1] Despite their prominent role in skeletal muscle protein metabolism, BCAAs are fractionally catabolised in other organs, including the liver and adipose tissue,[2] contributing to the upregulation of glucose transport and insulin secretion.[3] However, excessive BCAA consumption interferes with lipid oxidation in skeletal muscle,[4] leading to impaired insulin signalling.[3,5–7] Conversely, impaired insulin signalling may cause exacerbated skeletal muscle, adipose tissue and liver proteolysis,[8–10] which could potentially lead to high circulating levels of BCAAs.[11] Epidemiological evidence has proposed that insulin resistance (IR) may drive increased circulating fasting BCAA levels, as opposed to BCAA consumption being the primary driver of IR.[12] Indeed, a recent systematic review of observational studies has reported conflicting results on the association between intake of BCAAs and IR development, with two of the three reported studies suggesting a proportional relationship.[13]

BCAA supplementation has been reported to increase insulin secretion but with minimal influence on glyceamic responses,[14,15] as opposed to protein supplements such as whey protein, which may modulate glucose disposal in an insulin-dependent manner.[14,16–18] Particularly, an improved oral glucose sensitivity index and postprandial insulin secretion have been observed in humans following short (1 week)[19] and longer (4 and 8 weeks)[20,21] dietary BCAA intake restriction; however, longer trials may be warranted to elicit more clinically meaningful findings.

Hepatic disorders such as liver cirrhosis, hepatic encephalopathy and hepatocellular carcinoma are all characterised by decreased circulating BCAA levels.[22] Hepatic disorders have long been linked with impaired glucose tolerance and IR, which has more recently been observed to improve upon BCAA supplementation.[23–26] Indeed, BCAAs may increase peroxisome proliferator-activated receptor-γ and uncoupling protein (UCP)2 in the liver and UCP3 in skeletal muscle, stimulating free fatty acid oxidation and improving insulin sensitivity.[22] The effects of BCAA consumption on glycaemic profile may depend on dose, duration and individual health status. These observations of improved IR and glucose tolerance with BCAA supplementation contrast considerably with the association of elevated serum BCAAs with IR in some chronic diseases. The aim of this systematic review was to investigate the effects of isolated BCAA supplementation on markers of glucose metabolism in adults with various hepatic disorders.

METHODS

This systematic review was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)[27] guidelines and the protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (Registration number: CRD42022304636).

Search strategy

Two independent reviewers (KP and RK) searched PubMed, Scopus, Web of Science and Cochrane Library, using the following search terms: "BCAA" OR "branched chain amino acids" OR "leucine" AND "insulin" OR "blood glucose" OR "glycaemic" OR "blood sugar" OR "HbA1c" OR "HOMA-IR" AND "liver disease" OR "hepatic disorder" OR "cirrhosis" OR "hepatitis" OR "hepatocellular carcinoma" OR "portal vein embolisation" OR "hepatic encephalopathy". The full search strategy and search terms used are described in the Supporting information (Table S1). Discrepancies in the literature search process were resolved by a third and fourth investigator (PG and KKT).

Study eligibility

Studies were included based on the following inclusion criteria: (1) human studies in populations with hepatic disorders; (2) clinical trials; (3) BCAAs as an intervention group; and (4) oral route of administration. Studies were excluded based on the following exclusion criteria: (1) non-clinical trials; (2) BCAA co-ingestion with a mixed meal; (3) acute studies lasting < 7 days; and (4) full text not published.

Data extraction and risk of bias

Two reviewers (KP and RPK) extracted data based on name of first author, publication date, country of origin, study design, participant health status, age, sex, sample size, outcome measures, supplemental form, dose and duration. Disagreements between reviewers were resolved by a third and fourth investigator (PG and KSK). The quality of included studies was assessed using the Cochrane Risk-of-Bias 2 (RoB2) for randomised trials tool and evaluated by three independent reviewers (KP, PG and KKT). Appraisal of risk of bias using the RoB2 tool included assessment of the domains of bias in randomised controlled trials (RCTs): (1) randomisation process; (2) deviations from intended interventions; (3) missing outcome data; (4) measurement of the outcome; and (5) selection of the reported result.[28] According to the RoB2 tool scoring system, study quality was defined as low risk of bias, some concerns or high risk of bias. In addition, risk of bias assessment for the non-randomised (single arm) trials was performed using the Risk Of Bias In Non-Randomised Studies—of Interventions (ROBINS-I) tool that classifies studies based on bias due to: (1) confounding factors; (2) selection of participants into the study; (3) the classification of interventions; (4) deviations from intended interventions; (5) missing data; (6) outcome measurements; and (7) selection of the reported result.[29] According to ROBINS-I tool, the quality of studies was categorised as low, moderate or serious risk.

RESULTS

Search results

The literature search yielded 3403 publications. In total, 1318 duplicates were excluded, and 2085 publications were sought for retrieval. Following screening of tittles, abstracts and full texts, 20 studies were retrieved examining the effects of BCAA supplementation on markers of glucose metabolism. Of these, two studies had ineligible interventions, three had incompatible study population and four had missing data. Overall, 11 studies were deemed eligible for inclusion in the review (Figure 1).

Characteristics of the included studies

All relevant information pertained to participant characteristics are summarised in Table 1. Of the 11 studies, seven studies were conducted in Japan,[30–36] two in Mexico,[38,39] one in Italy[37] and one in Spain.[40] Two studies were conducted in individuals aged between 50 and 60 years[32,39] and nine in individuals ≥ 60 years.[30,31,33–38,40] All studies were cohorts of both males


FIGURE 1 Flowchart of the employed literature search

and females. Two studies did not provide relevant information pertained to the total number of males and females.[32,37]

Further, four studies were RCTs,[31,33,34,36] two were double-blinded RCTs,[37,40] one was a crossover, open-label RCT,[32] one was an open label RCT[39] and three were clinical trials.[30,35,38] Moreover, seven used BCAA supplementation alone,[30–34,37,38] three co-supplemented vitamins and minerals[35,36,40] of which one followed a physical activity protocol,[40] and one followed a high-protein/high-fibre diet.[39] BCCA supplementation ranged from 4 weeks to 48 months in terms of duration and from 2.4 to 30 g day^{-1} in terms of dosage.

Amongst the comparator groups, two studies used placebo controls,[37,40] of which one included physical activity,[40] one used an isocaloric control snack,[36] four used a usual diet regime,[31–34] one used a high-protein/high fibre diet[39] and three were single arm trials.[30,35,38]

Six studies included individuals with liver cirrhosis,[30,34,36,37,39,40] of which one experimented with sleep disturbance,[34] one with hepatocellular carcinoma (HCC),[33] two with hepatitis,[32,38] of which one included participants with insulin resistance,[32] one with portal vein embolisation (PVE) and sequential hepatectomy.[31]

Serum insulin

BCAA supplementation led to conflicting results regarding serum insulin levels. Specifically, 8 g day^{-1} of BCAA for 6 months, decreased serum insulin from 13.85 (6.6–18.6) U ml^{-1} to 7.9 (5.0–96.9) U ml^{-1} in patients undergoing PVE; however, similar changes were shown in the control group, which followed their usual diet

TABLE 1 Study and participant characteristics of the included studies

Reference (year)	Country	Study design	Total n (M/F)	BCAA n (M/F)	BCAA Age (SD)	Comparator n (M/F)	Comparator Age (SD)	Treatment dose (g day^{-1})	Treatment duration	Health status	Reported outcomes
Hernandez-Conde et al.[40]	Spain	Double-blind RCT	32 (28/4)	17 (15/2)	69 (9.7)	15 (13/2)	61 (9.4)	5.2	12 weeks	Cirrhosis	HOMA-IR
Ruiz-Margain et al.[39]	Mexico	Open-label RCT	72 (14/58)	37 (6/31)	54.9 (10.3)	35 (8/27)	47.8 (14.6)	8.6	6 months	Cirrhosis	Glucose
Kitajima et al.[30]	Japan	Clinical Trial	21 (9/12)	21 (9/12)	71.3 (7.9)	–	–	4	48 weeks	Cirrhosis	Insulin Glucose HOMA-IR
Ocana-Mondragon et al.[38]	Mexico	Clinical trial	20 (10/10)	20 (10/10)	53 (45.63)	–	–	30	3 months	Chronic hepatitis C	Insulin Glucose HOMA-IR
Beppu et al.[31]	Japan	RCT	28 (19/9)	13 (9/4)	64 (47–83)	15 (10/5)	72 (56–78)	8	6 months	PVE	Insulin Glucose HbA1c
Takeshita et al.[32]	Japan	Crossover, open label RCT	24	13	58.6 (2.9)	11	64.2 (3.0)	12.5	12 weeks	Hepatitis C IR	Insulin Glucose HOMA-IR HbA1c
Yoshiji et al.[33]	Japan	RCT	42 (26/16)	16 (10/6)	63.7 (10.8)	26 (16/10)	62.5 (11.5)	12	48 months	HCC	Glucose HOMA-IR
Ichikawa et al.[34]	Japan	RCT	21 (10/11)	12 (5/7)	66.2 (8.2)	9 (5/4)	67.4 (9.9)	13.5	8 weeks	Cirrhosis Sleep Disturbance	Glucose
Kawaguchi et al.[35]	Japan	Clinical Trial	12 (5/7)	12 (5/7)	64.3 (2.4)	–	–	6.4	90 days	Chronic liver disease	Insulin Glucose HOMA-IR HbA1c
Nakaya et al.[36]	Japan	RCT	38 (20/18)	19 (13/6)	67 (9)	19 (7/12)	67 (8)	12.3	3 months	Cirrhosis	Insulin Glucose
Marchesini et al.[37]	Italy	Double-blind RCT	61	29	60 (44–70)	32	60 (43–70)	2.4	3 months	Cirrhosis	Insulin Glucose

Abbreviations: BCAA, branched chain amino acid; F, female; HbA1c, glycated haemoglobin; HCC, hepatocellular carcinoma; HOMA-IR, homeostatic model assessment for insulin resistance; IR, insulin resistance; M, male; PVE, portal vein embolisation; RCT, randomised controlled trial.

(13.50 (4.4–18.8)–9.2 (2.7–38.8) U ml^{-1}).[31] Furthermore, another study in patients with liver cirrhosis showed that 3 months of 2.4 g day^{-1} BCAA slightly improved serum insulin (25 ± 17 to 23 ± 17 µU L^{-1}) compared to placebo (casein) group (19 ± 10 to 22 ± 17 µU L^{-1}), although no significant changes were observed.[37] By contrast, in patients with hepatitis C and insulin resistance, BCAA supplementation (12.5 g day^{-1}) increased serum insulin levels after 12 weeks (13.8 ± 1.6 to 17.8 ± 3.6 µU L^{-1}) as opposed to participants following their usual dietary patterns (23.3 ± 8.0 to 21.2 ± 4.6 µU L^{-1}).[32] Furthermore, another study showed a substantial increase of serum insulin (16.2 ± 6.8 to 32.9 ± 34.5 µU ml^{-1}) compared to an isocaloric control snack (21.3 ± 19.5 to 20.9 ± 14.4 µU ml^{-1}) in patients with liver cirrhosis.[36] However, in this case the supplementary product consisted of BCAAs alongside vitamins and minerals. In the single arm studies, a high BCAA dose (30 g day^{-1}) was slightly effective in reducing serum insulin levels (16 [11–31] to 14 [9–22] µU L^{-1}) in patients with chronic hepatitis C when administered for 30 months,[38] whereas another study displayed a significant decrease of serum insulin (22.8 ± 9.7 to 13.3 ± 1.9 µU ml^{-1}) after BCAA supplementation (6.4 g day^{-1}) with vitamins and minerals after 90 days in patients with chronic liver disease.[35] Finally, one study demonstrated a small increase in serum insulin (14.2 ± 11.8 to 15.7 ± 16.5 µU ml^{-1}) following a low BCAA dose (4 g day^{-1}) in patients with liver cirrhosis for 48 weeks.[30]

Serum glucose

Conflicting results were also observed on serum glucose after BCAA supplementation. In one study using 8.6 g day^{-1} BCAA,[39] a small increase in serum glucose levels in the intervention (110.8 ± 52.9 to 112 ± 52 mg dl^{-1}) group was observed as opposed to the control group (104.3 ± 45.4 to 94.1 ± 17.4 mg dl^{-1}) in patients with liver cirrhosis when administered 6 months. Likewise, another study displayed a similar trend following 12.3 g day^{-1} BCAA co-supplemented vitamins and minerals (107 ± 23 to 118 ± 39 mg dl^{-1}) compared to an isocaloric snack group (99 ± 26 to 95 ± 10 mg dl^{-1}).[36] Furthermore, another study also showed a small increase in the intervention (92.1 ± 2.1 to 96.6 ± 2.1 mg dl^{-1}) compared to the usual diet group (100.6 ± 2.9 to 96.2 ± 2.0 mg dl^{-1}).[32] On the other hand, a significant decrease in serum glucose levels (126.0 [75–184] to 98.0 (84–242) mg dl^{-1}) was reported after 6 months with 8 g day^{-1} BCAA supplementation compared to usual diet (101.0 [87–123 to 104.0 (90–125) mg dl^{-1}) in patients with PVE.[31] No changes were seen in serum glucose levels of patients with HCC between the intervention (102.7 ± 30.6 to 95.4 ± 31.1 mg dl^{-1}) and the control group (113.4 ± 28.8 to 107.8 ± 31.2 mg dl^{-1}) following 12 g day^{-1} for 48 months.[33] In addition, an identical trend was depicted in patients with liver cirrhosis and sleep disturbance after 13.5 g day^{-1} BCAA for 8 weeks (107.5 ± 27.2 to 105.7 ± 73.2 mg dl^{-1}) against usual diet (115.4 ± 27.2 to 111.6 ± 24.2 mg dl^{-1}).[34] In the single arm studies, serum glucose was reduced in each trial, however, no significant decrease was displayed (113.6 ± 31.7 to 108.5 ± 27.7 mg dl^{-1})[30]; (124.2 ± 9 to 120.6 [109.9–133.3] mg dl^{-1})[38]; (104.5 ± 6.4 to 102.8 ± 5.4 mg dl^{-1}).[35]

Glycated haemoglobin

No changes in HbA1c were observed following 12.45 g day^{-1} BCAA supplementation for 12 weeks compared to usual diet in IR patients with hepatitis C (5.0% ± 0.1% to 4.9% ± 0.1% vs. 4.9% ± 0.1% to 5.0% ± 0.1%).[32] Additionally, no changes on HbA1c were revealed after consumption of 6.4 g/day BCAA for 90 days (5.5% ± 0.2% to 5.4% ± 0.3%).[35]

Homeostatic model assessment for insulin resistance

The overall score of HOMA-IR was reduced following 5.2 g day^{-1} BCAA co-supplemented with vitamins, minerals and physical activity after 12 weeks (4.9 ± 6.7 to 3.2 ± 1.8); however, no differences were observed compared to the physical activity and placebo group (6.3 ± 8.6 to 4.7 ± 3.2).[40] Similarly, identical findings were identified following 12 g day^{-1} of BCAA supplementation for 12 weeks (3.55 ± 3.01 to 2.75 ± 2.08) against placebo (3.79 ± 2.92 to 3.61 ± 2.88).[33] Interestingly, an increase in HOMA-IR score was demonstrated after 12.45 g day^{-1} for 12 weeks of BCAA (3.2 ± 0.4 to 4.5 ± 1.1) compared to usual diet that reduced HOMA-IR (6.1 ± 2.2 to 5.3 ± 1.3).[32] In the single arm studies, BCAA supplementation led to a decrease in HOMA-IR after 90 days as observed in (5.5 ± 2.1 to 3.5 ± 0.6)[35] and (3.5 (2.6–7.9) to 3.2 (1.9–5.0).[38] Finally, a study revealed higher HOMA-IR scores following a 4 g day^{-1} BCAA dose for 48 weeks (3.9 ± 3.0 to 4.5 ± 5.4).[30]

Risk of bias

According to RoB2, risk of bias was high in one study[31] as a result of lack of information relevant to treatment allocation concealment and participants and trial personnel knowing about the type of intervention. Finally, some concerns were raised in three studies as a result of participants possibly knowing about the type of intervention.[32,34,36] A detailed traffic light plot is presented in Figure 2.

According to ROBINS-I, moderate risk of bias was displayed in one study as a result of insufficient control for confounders (i.e., physical activity).[30] Serious risk of

bias was observed in two studies as a result of no control for major confounding factors (i.e., diet and physical activity).[38] A detailed traffic light plot is presented in Figure 3.

DISCUSSION

In this systematic review, we identified 11 studies examining the effects of BCAA supplementation on markers of glucose metabolism in participants with hepatic disorders. Overall, BCAA supplementation resulted in small decreases in serum insulin and HOMA-IR scores with no effect on serum glucose levels or changes in HbA1c.

The maintenance of physiological serum glucose is an essential component of glucose homeostasis, with impaired glycaemic control linked to a greater risk of chronic diseases such as type 2 diabetes (T2D) and cardiovascular disease.[41,42] A contributing factor to poor glycaemic control is IR. Epidemiological data has shown that IR and clinical diagnoses of T2D and prediabetes are associated with elevated serum BCAAs.[43] By contrast to the observation of higher serum BCAA levels in those with IR or T2D, BCAA supplementation has been reported in some cases to improve measures of glucose homeostasis.[44] Recent research using Mendelian randomisation analysis has further clarified that elevated serum BCAAs are likely driven by the presence of IR and not the other way around (i.e., elevated serum BCAA do not drive IR).[12]

Animal models have revealed that a mechanism for the potentially beneficial effects of BCAA supplementation on glyceamic control is the activation of phosphoinositide-3 kinase (PI3K). This increase in insulin sensitivity and upregulation of glucose transporter protein 4 (GLUT4) may facilitate non-insulin mediated entry of glucose into cells.[45] Additional research in rat models has duplicated the observation of increased GLUT4 translocation to the skeletal muscle cell membrane as well as increased translocation of the GLUT1 glucose transporter protein.[46] The same research group observed an upregulation of glycogen synthase activity in leucine treated rats, which resulted in increased glycogen

content in soleus muscle compared to controls.[46] Such increased synthesis of glycogen by taking excess serum glucose out of circulation and storing it in skeletal muscle, could assist with overall glyceamic regulation.

Insulin sensitivity may be further affected by increased utilisation of glucose as fuel through glycolysis, via upregulation of GLUT2 and glucokinase in the liver, leading to improved bioactivity of the glucose-sensing apparatus.[47] Specifically, glucokinase is involved in the regulation of hepatic glycolysis and glucose oxidation, glycogen synthase, glycogenolysis and gluconeogenesis amongst others.[48] Therefore, BCAA supplementation may act as a partial substitute for insulin in glucose transport regulation by increasing glycogen synthesis in both skeletal muscle and liver. However, it should be noted that some research has reported conflicting results. Specifically, infusion of amino acids including leucine and isoleucine in human subjects has been reported to compete with glucose as an oxidative fuel, reducing glucose uptake.[49] Nevertheless, the aforementioned study involved venous infusion and not dietary supplementation of BCAAs, indicating that elevated serum levels of BCAAs may interfere with glyceamic control and not necessarily dietary intake.

Moreover, increased adiposity and in particular, skeletal muscle and liver tissue triglyceride (TG) accumulation are known to interfere with GLUT4 translocation and glucose uptake, mediated via the activation of insulin-stimulated PI3K, which may lead to IR.[50] In mouse models, supplementation with the BCAA isoleucine has been reported to reduce accumulation of TG in both skeletal muscle and liver tissue.[51,52] This is speculated to occur via upregulation of peroxisome proliferator-activated receptor-α and UCP2 in liver tissue and UCP3 in the skeletal muscle tissue. Thus, leading to increased free fatty acid oxidation, which results in improvements of insulin sensitivity induced by lipotoxicity.[51,53]

Limitations

This systematic review is the first to examine the effects of isolated BCAA supplementation on markers of glucose metabolism in patients with hepatic disorders. The prevailing limitation of this review was the inability to produce a meta-analysis as a result of the heterogeneity in study designs. The large heterogeneity in protocols that can be observed in the populations included, the varied dosage of BCAA supplementation (2.4–30 g day^{-1}), and study duration (4 weeks to 48 months). Furthermore, of the 11 studies included, seven involved Japanese populations, with the remaining four studies from the USA, Spain, Mexico and Italy, which may raise concerns regarding the generalisability of the results to other geographical regions or ethnicities. Finally, inconsistencies among dietary intakes among studies, in which

there was no control is a critical confounding factor in extrapolating more accurate conclusions regarding the effects of BCAA supplements in isolation.

CONCLUSIONS

This systematic review revealed limited effects of isolated BCAA supplementation on overall glucose homeostasis among individuals with hepatic disorders, however, some improvements on serum insulin and HOMA-IR scores were observed. Studies should be aware of controlling strictly for dietary intake to omit the potential impact of other nutrients on glucose homeostasis and incorporate a placebo group as a comparator that would reduce bias risk. BCAA supplementation as an independent strategy appears to may not be an effective tool in improving glucose homeostasis in patients with hepatic disorders.

AUTHOR CONTRIBUTIONS
Study concept and design: Konstantinos Prokopidis and Panagiotis Giannos. *Acquisition of data*: Konstantinos Prokopidis, Richard P. Kirwan and Konstantinos K. Triantafyllidis. *Analysis and interpretation of data*: Konstantinos Prokopidis, Richard P. Kirwan and Konstantinos S. Kechagias. *Drafting of the manuscript*: Konstantinos Prokopidis, Richard P. Kirwan and Panagiotis Giannos. *Critical revision of the manuscript for important intellectual content*: Konstantinos Prokopidis, Richard P. Kirwan, Panagiotis Giannos, Scott C. Forbes and Darren G. Candow.

CONFLICTS OF INTEREST
The authors declare that there are no conflicts of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

TRANSPARENCY DECLARATION
The lead author affirms that this manuscript is an honest, accurate and transparent account of the study being reported.

ORCID
Konstantinos Prokopidis http://orcid.org/0000-0002-6264-9388
Panagiotis Giannos http://orcid.org/0000-0003-1037-1983
Konstantinos S. Kechagias http://orcid.org/0000-0001-6681-8479

REFERENCES

1. White JP. Amino acid trafficking and skeletal muscle protein synthesis: a case of supply and demand. Front Cell Dev Biol. 2021;9: 656604.

2. Brosnan JT, Brosnan ME. Branched-chain amino acids: enzyme and substrate regulation. J Nutr. 2006;136:207S–211S.

3. Zhou M, Shao J, Wu C-Y, Shu L, Dong W, Liu Y, et al. Targeting BCAA catabolism to treat obesity-associated insulin resistance. Diabetes. 2019;68:1730–46.

4. White PJ, Lapworth AL, An J, Wang L, Mcgarrah RW, Stevens RD, et al. Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export. Mol Metab. 2016;5:538–51.

5. Crossland H, Smith K, Idris I, Phillips BE, Atherton PJ, Wilkinson DJ. Exploring mechanistic links between extracellular branched-chain amino acids and muscle insulin resistance: an in vitro approach. Am J Physiol-Cell Physiol. 2020;319:C1151–57.

6. Jang C, Oh SF, Wada S, Rowe GC, Liu L, Chan MC, et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nature Med. 2016;22: 421–426.

7. Tremblay F, Lavigne C, Jacques H, Marette A. Role of dietary proteins and amino acids in the pathogenesis of insulin resistance. Annu Rev Nutr. 2007;27:293–310.

8. Cheng S, Wiklund P, Autio R, Borra R, Ojanen X, Xu L, et al. Adipose tissue dysfunction and altered systemic amino acid metabolism are associated with non-alcoholic fatty liver disease. PLoS One. 2015;10:e0138889.

9. Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, et al. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids. 2015;47:603–15.

10. Lerin C, Goldfine AB, Boes T, Liu M, Kasif S, Dreyfuss JM, et al. Defects in muscle branched-chain amino acid oxidation contribute to impaired lipid metabolism. Mol Metab. 2016;5:926–36.

11. White PJ, Mcgarrah RW, Herman MA, Bain JR, Shah SH, Newgard CB. Insulin action, type 2 diabetes, and branched-chain amino acids: a two-way street. Mol Metab. 2021;52:101261.

12. Mahendran Y, Jonsson A, Have CT, Allin KH, Witte DR, Jørgensen ME, et al. Genetic evidence of a causal effect of insulin resistance on branched-chain amino acid levels. Diabetologia. 2017;60:873–8.

13. Vieira EES, Pereira IC, Braz AF, Nascimento-Ferreira MV, De Oliveira Torres LR, De Freitas Brito A, et al. Food consumption of branched chain amino acids and insulin resistance: a systematic review of observational studies in humans. Clin Nutr ESPEN. 2020;40:277–81.

14. Smith GI, Yoshino J, Stromsdorfer KL, Klein SJ, Magkos F, Reeds DN, et al. Protein ingestion induces muscle insulin resistance independent of leucine-mediated mTOR activation. Diabetes. 2015;64:1555–63.

15. Zhang Y, Kobayashi H, Mawatari K, Sato J, Bajotto G, Kitaura Y, et al. Effects of branched-chain amino acid supplementation on plasma concentrations of free amino acids, insulin, and energy substrates in young men. J Nutr Sci Vitaminol. 2011;57:114–117.

16. Pal S, Ellis V, Dhaliwal S. Effects of whey protein isolate on body composition, lipids, insulin and glucose in overweight and obese individuals. Br J Nutr. 2010;104:716–23.

17. Smith K, Bowden Davies KA, Stevenson EJ, West DJ. The clinical application of mealtime whey protein for the treatment of postprandial hyperglycaemia for people with type 2 diabetes: a long whey to go. Front Nutr. 2020;7:209.

18. Stevenson EJ, Allerton DM. The role of whey protein in postprandial glycaemic control. Proc Nutr Soc. 2018;77:42–51.

19. Ramzan I, Taylor M, Phillips B, Wilkinson D, Smith K, Hession K, et al. A novel dietary intervention reduces circulatory branched-chain amino acids by 50%: a pilot study of relevance for obesity and diabetes. Nutrients. 2021;13:95.

20. Fontana L, Cummings NE, Apelo SIA, Neuman JC, Kasza I, Schmidt BA, et al. Decreased consumption of branched-chain amino acids improves metabolic health. Cell Rep. 2016;16:520–30.

21. Karusheva Y, Koessler T, Strassburger K, Markgraf D, Mastrototaro L, Jelenik T, et al. Short-term dietary reduction of branched-chain amino acids reduces meal-induced insulin secretion and modifies microbiome composition in type 2 diabetes: a randomized controlled crossover trial. Am J Clin Nutr. 2019;110: 1098–107.

22. Tajiri K, Shimizu Y. Branched-chain amino acids in liver diseases. World J Gastroenterol. 2013;19:7620–9.

23. Kato M, Miwa Y, Tajika M, Hiraoka T, Muto Y, Moriwaki H. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. Intern Med. 1998;37: 429–34.

24. Park JG, Tak WY, Park SY, Kweon YO, Jang SY, Lee YR, et al. Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: a Korean nationwide, multicenter, retrospective, observational, cohort study. Medicine. 2017;96: e6580.

25. Sakaida I, Tsuchiya M, Okamoto M, Okita K. Late evening snack and the change of blood glucose level in patients with liver cirrhosis. Hepatol Res. 2004;30:67–72.

26. Sato S, Watanabe A, Muto Y, Suzuki K, Kato A, Moriwaki H, et al. Clinical comparison of branched-chain amino acid (l-Leucine, l-Isoleucine, l-Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV–EN study). Hepatol Res. 2005;31:232–40.

27. Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

28. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:5928.

29. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:4919.

30. Kitajima Y, Takahashi H, Akiyama T, Murayama K, Iwane S, Kuwashiro T, et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis. J Gastroenterol. 2018;53:427–37.

31. Beppu T, Nitta H, Hayashi H, Imai K, Okabe H, Nakagawa S, et al. Effect of branched-chain amino acid supplementation on functional liver regeneration in patients undergoing portal vein embolization and sequential hepatectomy: a randomized controlled trial. J Gastroenterol. 2015;50:1197–205.

32. Takeshita Y, Takamura T, Kita Y, Ando H, Ueda T, Kato K, et al. Beneficial effect of branched-chain amino acid supplementation on glycemic control in chronic hepatitis C patients with insulin resistance: implications for type 2 diabetes. Metabolism. 2012;61:1388–94.

33. Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Yamazaki M, et al. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep. 2011;26:1547–53.

34. Ichikawa T, Naota T, Miyaaki H, Miuma S, Isomoto H, Takeshima F, et al. Effect of an oral branched chain amino acid-enriched snack in cirrhotic patients with sleep disturbance. Hepatol Res. 2010;40:971–8.

35. Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med. 2008;22:105–12.

36. Nakaya Y, Okita K, Suzuki K, Moriwaki H, Kato A, Miwa Y, et al. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition. 2007;23:113–20.

37. Marchesini G, Dioguardi F, Bianchi G, Zoli M, Bellati G, Roffi L, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy: a randomized double-blind casein-controlled trial. J Hepatol. 1990;11:92–101.

38. Ocaña-Mondragón A, Mata-Marín JA, Uriarte-López M, Bekker-Méndez C, Alcalá-Martínez E, Ribas-Aparicio RM, et al. Effect of branched-chain amino acid supplementation on insulin resistance and quality of life in chronic hepatitis C patients. Biomed Rep. 2018;8:85–90.

39. Ruiz-Margáin A, Macías-Rodríguez R, Ríos-Torres S, Román-Calleja B, Méndez-Guerrero O, Rodríguez-Córdova P, et al. Effect of a high-protein, high-fiber diet plus supplementation with branched-chain amino acids on the nutritional status of patients with cirrhosis. Rev Gastroenterol Méx. 2018;83:9–15.

40. Hernández-Conde M, Llop E, Gómez-Pimpollo L, Fernández Carrillo C, Rodríguez L, Van Den Brule E, et al. Adding branched-chain amino acids to an enhanced standard-of-care treatment improves muscle mass of cirrhotic patients with sarcopenia: a placebo-controlled trial. Am J Gastroenterol. 2021;116:2241–49.

41. Nichols GA, Joshua-Gotlib S, Parasuraman S. Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. JACC. 2013;62:121–7.

42. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. JACC. 2009;53:298–304.

43. Long J, Yang Z, Wang L, Han Y, Peng C, Yan C, et al. Metabolite biomarkers of type 2 diabetes mellitus and pre-diabetes: a systematic review and meta-analysis. BMC Endocr Disord. 2020;20:1–17.

44. Yoshizawa F. New therapeutic strategy for amino acid medicine: notable functions of branched chain amino acids as biological regulators. J Pharmacol Sci. 2012;118:149–55.

45. Zhu X, Wang W, Cui C. Hypoglycemic effect of hydrophobic BCAA peptides is associated with altered PI3K/Akt protein expression. J Agric Food Chem. 2021;69:4446–52.

46. Nishitani S, Takehana K, Fujitani S, Sonaka I. Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. Am J Physiol-Gastrointest Liver Physiol. 2005;288: G1292–300.

47. Higuchi N, Kato M, Miyazaki M, Tanaka M, Kohjima M, Ito T, et al. Potential role of branched-chain amino acids in glucose metabolism through the accelerated induction of the glucose-sensing apparatus in the liver. J Cell Biochem. 2011;112:30–8.

48. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov. 2009;8:399–416.

49. Schwenk WF, Haymond MW. Decreased uptake of glucose by human forearm during infusion of leucine, isoleucine, or threonine. Diabetes. 1987;36:199–204.

50. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171–6.

51. Arakawa M, Masaki T, Nishimura J, Seike M, Yoshimatsu H. The effects of branched-chain amino acid granules on the accumulation of tissue triglycerides and uncoupling proteins in diet-induced obese mice. Endocr J. 2011;58:161–70.

52. Nishimura J, Masaki T, Arakawa M, Seike M, Yoshimatsu H. Isoleucine prevents the accumulation of tissue triglycerides and upregulates the expression of PPARα and uncoupling protein in diet-induced obese mice. J Nutr. 2010;140:496–500.

53. Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, et al. Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000;275:16638–42.

AUTHOR BIOGRAPHIES

Konstantinos Prokopidis is a PhD(c) in Musculo-skeletal Biology and Clinical Nutrition at University of Liverpool interested in sarcopenia, frailty and inflammation.

Richard P. Kirwan is a PhD(c) in Clinical Nutrition and Post-Doctoral Researcher at LJMU with an interest in the role of protein, dietary patterns and exercise on muscle mass and cardiometabolic disease risk.

Panagiotis Giannos is a Biomedical Scientist pursuing a PhD degree focused on mechanisms of sleep and sleep regulation at Imperial College London.

Konstantinos K. Triantafyllidis is a Bariatric Dietitian with an interest in nutritional assessment methods, bariatric surgery and gastroenterology.

Dr Konstantinos S. Kechagias is a Medical doctor working as a Specialty Trainee in Obstetrics and Gynaecology and pursuing a PhD degree at Imperial College London.

Dr Scott C. Forbes is an Associate Professor at Brandon University, Manitoba, Canada. His main research area examines the interaction of nutrition and exercise.

Dr Darren G. Candow is a Professor and Director of the Aging Muscle and Bone Health Laboratory at the University of Regina, Canada. Dr Candow's research focuses on creatine monohydrate and resistance training on musculoskeletal ageing.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.